Objective. To study the effectiveness of non-invasive prenatal testing (NIPT) for trisomy 21, 18, and 13 in twin pregnancy, by using a meta-analysis. Materials and methods. The meta-analysis was carried out in accordance with the user’s guide for writing a meta-analysis, which had been recommended by the Cochrane community 2016. The investigators analyzed the literature found in the largest databases: MEDLINE via PubMed, EMBASE, CENTRAL (Cochrane Library), ClinicalTrials.gov, and the World Health Organization International Clinical Trials Registry Platform (ICTRP). The indicators were estimated by the meta-analysis using Review Manager 5.4.1 (Cochrane col., UK). Results. A total of 19 trials were selected and analyzed. A total of 7138 pregnant women were included in the meta-analysis. The latter revealed that the sensitivity and specificity of NIPT for trisomy 21, 18, and 13 in the fetus were 0.98 (95% CI 0.75–1.00), 0.99 (95% CI 0.99–1.00), and 0.97 (95% CI 0.5–1.00), and 0.99 (95% CI 0.99–1.00), 0.875 (95% CI 0–1.00), and 0.99 (95% CI 0.99–1.00), respectively. Conclusion. NIPT demonstrates the high efficiency of detecting trisomy 21 and 18, which is comparable to singlet pregnancy. The authors could not significantly evaluate the effectiveness of NIPT for trisomy 13, due to the insufficient number of trials, in which the pregnancies at increased risk for trisomy 13 were identified.